Eli Lilly and Company
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, Eli Lilly and Company sits in the top decile of US sponsors by registered trial count (#18 of 15,742 sponsors by registered trial count).
Eli Lilly and Company: 1,341 sponsored US clinical trials, 124 recruiting.
Eli Lilly and Company sponsors 1,341 registered US clinical trials on ClinicalTrials.gov, 124 of them currently recruiting, and 1,029 completed. 459 of these trials are in Phase 3-4 (later-stage) and 861 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Healthy, with 55 trials.
Top-decile sponsor footprint
Eli Lilly and Company ranks in the top decile of sponsors by registered trial count (#18 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
1,029 of 1,131 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (91.0%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
1,341 total, page 8 of 27
A Study of Tirzepatide (LY3298176) In Participants After A Lifestyle Weight Loss Program
NCT04657016
A Study of Tirzepatide (LY3298176) in Participants With Type 2 Diabetes Who Have Obesity or Are Overweight
NCT04657003
A Study of Tirzepatide (LY3298176) in Participants With Obesity or Overweight for the Maintenance of Weight Loss
NCT04660643
A Study of LY3540378 in Healthy Participants
NCT04768855
A Drug Drug Interaction (DDI) Study of Pirtobrutinib (LOXO-305) and Digoxin (P-Glycoprotein Substrate) in Healthy Participants
NCT06194214
A Study of LY3410738 in Healthy Adult Participants
NCT06181045
A Study of Ramucirumab (LY3009806) Given by Injection Under the Skin in Participants With Advanced Cancer
NCT04557384
A Study of LY3549492 in Healthy Participants
NCT04758234
A Real World Study of Bamlanivimab in Participants With Mild-to-Moderate Coronavirus Disease 2019 (COVID-19)
NCT04701658
Study of Pirtobrutinib (LOXO-305) in Participants With Impaired Kidney Function and Healthy Participants
NCT06190678
Abemaciclib (LY2835219) in Men With Heavily Treated Metastatic Castration-Resistant Prostate Cancer
NCT04408924
A Study to Evaluate LY3154207 on the Brain of Healthy Participants
NCT04258826
A Study of Effect of Multiple Doses of LOXO-305 on the Pharmacokinetics of Single Oral Doses of CYP1A2, CYP2C9, CYP2C19 Substrates in Healthy Participants
NCT06215430
A Study of LY3462817 in Participants With Rheumatoid Arthritis
NCT04634253
A Study of the Effect of Food on Pirtobrutinib (LOXO-305) in Healthy Participants
NCT06180980
Study of Pirtobrutinib (LOXO-305) in Participants With Impaired Liver Function and Healthy Participants
NCT06190691
A Study to Evaluate the Effect of Pirtobrutinib (LOXO-305) on QTc Interval in Healthy Participants
NCT06215521
A Study of LY3561774 in Participants With Dyslipidemia
NCT04644809
A Follow-On Study of Donanemab (LY3002813) With Video Assessments in Participants With Alzheimer's Disease (TRAILBLAZER-EXT)
NCT04640077
A Study of Lebrikizumab (LY3650150) on Vaccine Response in Adults With Atopic Dermatitis (ADopt-VA)
NCT04626297
A Study of LY3451838 in Participants With Migraine
NCT04498910
Chronic Pain Master Protocol (CPMP): A Study of LY3556050 in Participants With Osteoarthritis
NCT04627038
A Study of the Effects of Pirtobrutinib (LOXO-305) on Repaglinide (CYP2C8 Substrate) in Healthy Participants
NCT06165146
A Study of Abemaciclib (LY2835219) in Combination With Other Anti-Cancer Treatments in Children and Young Adult Participants With Solid Tumors, Including Neuroblastoma
NCT04238819
A Study of Mealtime Insulin LY900014 in Participants With Type 2 Diabetes Using Continuous Glucose Monitoring (PRONTO-Time in Range)
NCT04605991
A Study of Mirikizumab in Healthy Participants
NCT04607733
A Study of LY3832479 (LY-CoV016) in Healthy Participants 1
NCT04611789
A Study of LY900014 and Insulin Degludec in Participants With Type 1 Diabetes
NCT04585776
A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness
NCT04634409
A Study of LY3509754 in Healthy Non-Japanese and Japanese Participants
NCT04586920
A Study of Tirzepatide (LY3298176) Versus Insulin Lispro (U100) in Participants With Type 2 Diabetes Inadequately Controlled on Insulin Glargine (U100) With or Without Metformin
NCT04537923
A Study of LY3522348 in Healthy Participants
NCT04559568
A Study of LY3502970 in Participants With Type 2 Diabetes
NCT04426474
A Study of Gastrointestinal Emptying Time in Adult Participants With Migraine Before and After Start of a mAb CGRP Antagonist
NCT04294147
Safety & Efficacy of Encapsulated Allogeneic FVIII Cell Therapy in Haemophilia A
NCT04541628
A Study of Carbon-14-Labelled [14C] LOXO-305 (Pirtobrutinib) in Healthy Male Participants
NCT06180954
A Study to Measure Stomach Emptying in Overweight Non-diabetic and Diabetic Participants Using Tirzepatide
NCT04407234
A Study to Compare Two Different Formulations of Mirikizumab in Healthy Participants
NCT04548219
A Drug Drug Interaction (DDI) Study of Pirtobrutinib (LOXO-305) and Different Formulations of Midazolam in Healthy Participants
NCT06180967
A Study of LY3819253 (LY-CoV555) in Healthy Participants
NCT04537910
A Study of LY3041658 in Adults With Hidradenitis Suppurativa
NCT04493502
A Study of LY3493269 in Participants With Type 2 Diabetes
NCT04515576
Chronic Pain Master Protocol (CPMP): A Study of LY3016859 in Participants With Chronic Low Back Pain
NCT04529096
A Study of Tirzepatide in Overweight and Very Overweight Participants
NCT04311411
A Study to Evaluate Pirtobrutinib (LOXO-305) in Healthy Adult Participants
NCT06181006
A Study of the Effects of Multiple Doses of LY3372689 on the Brain in Healthy Participants
NCT04392271
A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Preventing SARS-CoV-2 Infection and COVID-19 in Nursing Home Residents and Staff
NCT04497987
A Study of Ramucirumab (LY3009806) in Healthy Participants
NCT04495478
Chronic Pain Master Protocol (CPMP): A Study of LY3016859 in Participants With Diabetic Peripheral Neuropathic Pain
NCT04476108
A Study of an Insulin Management System in Participants With Type 1 or Type 2 Diabetes
NCT04484779
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 517 |
| Phase 2 | 344 |
| Phase 3 | 368 |
| Phase 4 | 91 |
Therapeutic Areas
What is open in the Eli Lilly and Company pipeline
124 recruiting of 1,341 indexed (9% open); 1,029 completed (77%).
Phase mix: 459 late (III/IV) vs 861 early (I/II) (early-phase heavy).
Top condition: Healthy (55 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
Eli Lilly and Company: open-pipeline peers nationwide
Peers matched on 1,341 registered trials and 9% open enrollment, not the therapeutic-area sidebar.
Eli Lilly and Company sits at or above the median trial volume and below the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 1,341 trials (± recruiting share)
- GlaxoSmithKline · 1,345 trials · 4% recruiting
- University of Michigan · 1,327 trials · 13% recruiting
- Novartis Pharmaceuticals · 1,375 trials · 8% recruiting
- AstraZeneca · 1,285 trials · 12% recruiting
Sponsors near 9% open enrollment (± trial volume)
- Shionogi · 9% recruiting · 54 trials
- University of Kentucky · 9% recruiting · 54 trials
- University of Vermont · 9% recruiting · 162 trials
- Lahey Clinic · 9% recruiting · 43 trials
Related
What to do with this Eli Lilly and Company page
1,341 registered trials is a research-attention snapshot, not an endorsement of Eli Lilly and Company or any single study.
- 124 of Eli Lilly and Company's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Healthy is the condition Eli Lilly and Company studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Healthy trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Eli Lilly and Company pipeline card: 1,341 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.